PLK4 Inhibitor Combination Therapy for Refractory AML and MDS

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

There is a need for new drugs to treat acute myeloid leukemia (AML), chronic myeloid leukemia (CML), and myelodysplastic syndrome (MDS), particularly those with complex karyotypes and relapsed or refractory cases, as existing treatments are inadequate.

Innovation Solution

The use of Compound (I), a PLK4 inhibitor, in combination with standard of care agents like Venetoclax and 5-Azacytidine, to treat AML, CML, non-Hodgkin's lymphoma, Burkitt lymphoma, and MDS, including complex karyotype cases, through oral and parenteral administration.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If existing treatments are used for AML and MDS, then current standard therapy is maintained, but treatment efficacy is inadequate especially for complex karyotype cases

Engineering Contradiction:

Improvetreatment efficacyVSAvoidsuitability for complex karyotype cases

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent applies parameter changes by introducing a novel chemical compound (PLK4 inhibitor) with different pharmacological properties compared to existing AML/MDS treatments. This new compound targets polo-like kinase 4, a different molecular pathway than conventional therapies, thereby improving treatment efficacy particularly for complex karyotype cases that are resistant to standard treatments

Inventive Principle:

Principle #35Parameter changes

2Adaptability or versatility

If new drugs are developed to treat AML, CML, and MDS, then treatment options are expanded, but drug development complexity increases

Engineering Contradiction:

Improvetreatment optionsVSAvoiddrug development complexity

Core Design Contradiction:

Adaptability or versatilityVSDevice complexity

Solution Approach 1:

The patent extracts and isolates the specific therapeutic effect of PLK4 inhibition from the complex landscape of cancer therapies. By focusing on a single kinase target (PLK4) and developing a dedicated inhibitor compound, the patent simplifies the drug development approach while expanding treatment options for AML, CML, and MDS, avoiding the need to develop broad-spectrum multi-target agents

Inventive Principle:

Principle #2Taking out (Extraction)

3Reliability

If combination therapy with Venetoclax and 5-Azacytidine is used, then synergistic activity is achieved, but treatment complexity increases

Engineering Contradiction:

Improveanticancer activityVSAvoidcombination regimen complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent merges Compound (I) with existing standard-of-care agents Venetoclax and 5-Azacytidine to create a combination therapy regimen. This merging of therapies produces synergistic anticancer activity against AML and MDS, particularly demonstrating enhanced efficacy in complex karyotype cases, while the patent manages the complexity through structured combination protocols

Inventive Principle:

Principle #5Merging (Combining)

Data Source

PatentUS12533357B2Treatment for acute myeloid leukemia or myelodysplastic syndrome

Publication Date: 2026.01.27 UNIV HEALTH NETWORK

AI summary

The invention is related to a method of treating a subject with acute myeloid leukemia, acute lymphoblastic leukemia, chronic myeloid leukemia, non-Hodgkin's lymphoma, Burkitt lymphoma, or diffuse large B-cell lymphoma, or myelodysplastic syndrome by administration of Compound (I): (I), or a pharmaceutically acceptable salt thereof.